These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36619222)

  • 1. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
    Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
    Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
    Gross AM; Dombi E; Widemann BC
    Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Anderson MK; Johnson M; Thornburg L; Halford Z
    Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
    Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
    Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of selumetinib on pediatric elephantiasis neuromatosa.
    Blegen K; Ortiz-Romero SE; Juarez O; Voeller J
    Pediatr Dermatol; 2022 Sep; 39(5):764-766. PubMed ID: 35739628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
    N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
    Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
    J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing.
    Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Raghunathan A; Schwartz J; Spinner RJ
    J Neurooncol; 2024 Aug; 169(1):147-153. PubMed ID: 38739187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular Signal-Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I.
    Wang W; Cui XW; Gu YH; Wei CJ; Li YH; Ren JY; Chung MH; Aimaier RH; Zhang HB; Li QF; Wang ZC
    J Invest Dermatol; 2022 Mar; 142(3 Pt A):613-623.e7. PubMed ID: 34534577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
    Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
    Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
    Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
    Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
    Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
    Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibitors in RASopathies.
    Bergqvist C; Wolkenstein P
    Curr Opin Oncol; 2021 Mar; 33(2):110-119. PubMed ID: 33395032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
    Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
    Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
    Acar S; Armstrong AE; Hirbe AC
    Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
    Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
    ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.